TherapeuticsMD (NASDAQ:TXMD) Stock Price Down 1.5% – Here’s Why

Shares of TherapeuticsMD, Inc. (NASDAQ:TXMD) traded down 1.5% on Wednesday . The company traded as low as $1.91 and last traded at $1.94. 16,607 shares were traded during mid-day trading, a decline of 45% from the average session volume of 30,226 shares. The stock had previously closed at $1.97.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of TherapeuticsMD in a research report on Thursday, July 2nd. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat, TherapeuticsMD currently has an average rating of “Sell”.

TherapeuticsMD Stock Up 2.0%

The company has a 50 day simple moving average of $2.04 and a two-hundred day simple moving average of $2.13. The company has a market capitalization of $24.07 million, a P/E ratio of 34.67 and a beta of 0.59.

TherapeuticsMD (NASDAQ:TXMD) last posted its quarterly earnings data on Tuesday, May 12th. The company reported $0.01 earnings per share (EPS) for the quarter, beating the consensus estimate of ($6.12) by $6.13. The business had revenue of $0.72 million during the quarter, compared to analyst estimates of $19.77 million. TherapeuticsMD had a return on equity of 0.32% and a net margin of 5.34%.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the company. Citadel Advisors LLC raised its stake in shares of TherapeuticsMD by 125.5% in the third quarter. Citadel Advisors LLC now owns 34,273 shares of the company’s stock valued at $36,000 after acquiring an additional 19,073 shares during the period. Renaissance Technologies LLC boosted its stake in shares of TherapeuticsMD by 171.8% during the 4th quarter. Renaissance Technologies LLC now owns 96,500 shares of the company’s stock worth $157,000 after purchasing an additional 61,000 shares during the period. Finally, Tejara Capital Ltd boosted its stake in shares of TherapeuticsMD by 1.9% during the 4th quarter. Tejara Capital Ltd now owns 350,852 shares of the company’s stock worth $572,000 after purchasing an additional 6,649 shares during the period. Institutional investors own 30.74% of the company’s stock.

TherapeuticsMD Company Profile

TherapeuticsMD, Inc (NASDAQ:TXMD) is a women’s healthcare company dedicated to the development and commercialization of hormone therapy and contraceptive products. The company’s primary focus lies in addressing unmet needs in menopause management and birth control by offering innovative, non-estrogen alternatives designed to improve patient convenience and adherence. TherapeuticsMD operates in the United States, serving women through a specialty care distribution network that includes physician practices, clinics and pharmacies.

Among its flagship products is IMVEXXY, an FDA-approved low-dose vaginal estradiol insert indicated for the treatment of moderate to severe dyspareunia due to menopause.